Antimicrobial resistance

NASA Science, Hardware Aboard SpaceX's 30th Resupply Launch to Station

Retrieved on: 
Thursday, March 21, 2024
Falcon 9, Biotechnology, Artemis, Antimicrobial resistance, Gateway, Light, International Space Station, Astrobee, 3D, EDT, Television, Spacecraft, Biology, Moon, NASA, Multimedia, SpaceX, NASA TV, Dragon, Communications satellite

SpaceX's Dragon resupply spacecraft, carrying more than 6,000 pounds of cargo to the orbiting laboratory, launched on the company's Falcon 9 rocket at 4:55 p.m. EDT Thursday, from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida.

Key Points: 
  • SpaceX's Dragon resupply spacecraft, carrying more than 6,000 pounds of cargo to the orbiting laboratory, launched on the company's Falcon 9 rocket at 4:55 p.m. EDT Thursday, from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida.
  • The cargo spacecraft is scheduled to autonomously dock at the space station on Saturday, March 23, at approximately 7:30 a.m. and remain at the orbital outpost for about a month.
  • Live coverage of the arrival will begin at 5:30 a.m. on NASA+, NASA Television, and on the agency's website .
  • Learn more about NASA commercial resupply services missions at:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/nasa-science-hardware-aboard-sp...

Magnolia Medical Technologies Marks World AMR Awareness Week by Recognizing the Need to Reduce Antibiotic Usage through Accurate Blood Culture Results

Retrieved on: 
Monday, November 20, 2023
Select, CDI, Safety, Entrepreneurship, Fungal infection, WHO, AVP, Risk, Government, RN, WAAW, Sepsis, Patient, Infection, Antimalarial medication, Death, Drug resistance, Health, AMR, Invention, Acute kidney injury, Cancer, Diagnosis, Blood culture, Antimicrobial resistance, Hospital, Clostridioides difficile infection, Public, Education, Bloodstream infections, Pharmaceutical industry, Nursing

SEATTLE, Nov. 20, 2023 /PRNewswire/ -- In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis tests, is driving efforts to highlight the role of diagnostic stewardship in combating the risk of AMR.

Key Points: 
  • Accurate blood culture results prevent patients from receiving unnecessary, prolonged, and potentially harmful antibiotic therapies, and associated preventable clinical complications, including acute kidney injury, Clostridioides difficile infection (CDI), and multidrug-resistant organism (MDRO) infections.
  • We recently completed a survey of over 1,000 Americans that highlighted the public and medical community's concern with the issue of AMR."
  • Magnolia Medical is encouraging everyone to "Go Blue" from November 18 to 24 to raise awareness for AMR and the need for continued education of this issue.
  • Please visit VoicesofSepsis.org to encourage action from your congressional representatives to support patient safety measures that also help combat the threat of AMR.

Pharma Leader Dr. Holger Zimmermann Joins Lysando's Advisory Board in Pioneering Fight Against Antibiotic-Resistant Bacteria

Retrieved on: 
Wednesday, November 8, 2023
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Knowledge, Hope, Antimicrobial resistance, Advisory board, Pharmaceutical Advertising Advisory Board, Development, Multimedia, Pharmaceutical industry, Vaccine

Lysando, a leading innovator in the fight against antibiotic-resistant bacteria, proudly announces the appointment of Dr. Holger Zimmermann to its Advisory Board.

Key Points: 
  • Lysando, a leading innovator in the fight against antibiotic-resistant bacteria, proudly announces the appointment of Dr. Holger Zimmermann to its Advisory Board.
  • His extensive background in human pharmaceutical pre-clinical and clinical research underscores the transformative potential he brings to Lysando.
  • Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando, expresses his enthusiasm, stating, “We are delighted to welcome Dr. Holger Zimmermann to our Advisory Board.
  • Expressing his excitement to join Lysando, Dr. Holger Zimmermann states, “Lysando's Artilysin® technology represents a powerful tool to combat antibiotic-resistant germs.

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

Retrieved on: 
Tuesday, September 19, 2023
Staphylococcus, MIC, CLSI, Clinical trial, Medical microbiology, Staphylococcus aureus, Patient, Antimicrobial resistance, Clinical and Laboratory Standards Institute, Drug development, Challenge, Campaign, AST, Laboratory, Conference, Clinical, Knee, Peptide, Sosa, Pharmaceutical industry

Dr. Ambler’s presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therapeutic agents and the implications for clinical development.

Key Points: 
  • Dr. Ambler’s presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therapeutic agents and the implications for clinical development.
  • She will highlight and discuss various antibiotics in current use and several investigational agents that require a modified AST method, such as the Company’s DLAs.
  • Review and approval of new AST methods by standards development organizations, such as the Clinical and Laboratory Standards Institute (CLSI), is essential.
  • The Company will be presenting two posters describing the initial development of the exebacase MIC method for testing Staphylococci other than Staphylococcus aureus (SoSA) and method verification studies performed to evaluate test performance.

STRONGER ANIMAL WELFARE PROVISIONS KEY TO LOWERING THE USE OF ANTIMICROBIALS IN ANIMAL AGRICULTURE

Retrieved on: 
Tuesday, September 19, 2023
Heart, Human, Infection, Public, Policy, Food safety, Food, AMR, Category, Government, Ventilation, British Columbia Basic Income Expert Panel Report, Animal, Antimicrobial resistance, Risk, European, Federation, Health, Environment, Farm, Disease, Food preservation, Poultry farming, Aquaculture, Renewable energy

TORONTO, Sept. 19, 2023 /CNW/ - A new report from World Animal Protection Canada illustrates the dangers of continued inaction on the overuse of antimicrobials in animal agriculture and the solutions for government and industry.

Key Points: 
  • TORONTO, Sept. 19, 2023 /CNW/ - A new report from World Animal Protection Canada illustrates the dangers of continued inaction on the overuse of antimicrobials in animal agriculture and the solutions for government and industry.
  • Reducing antibiotic use in farming through improvements to animal welfare outlines why the overuse of antimicrobials in animal agriculture is dangerous, and how stronger animal welfare provisions across animal agriculture industries, is key to lowering the use of antimicrobials in Canada.
  • "The reality is if Canada implemented stronger animal welfare policies and infection control provisions in animal agriculture, antimicrobial use could be significantly lessened or even eliminated," said Lynn Kavanagh, World Animal Protection Canada's Farming Campaign Manager.
  • In 2022, the European Union banned prophylactic use of antimicrobials in animal agriculture.

Biosenta announces further advances in research and development of Tri-Filler™

Retrieved on: 
Tuesday, August 8, 2023
Canada, Calcium carbonate, Plastic, University of Calgary, University, Human, CSE, Failure, Paint, COVID-19, Ageing, Gram-negative bacteria, Germ, Global health, Research, AMR, Department of Chemical Engineering, Imperial College London, Carbon, Fungus, CDC, Candida auris, Pseudomonas aeruginosa, Genetically modified bacteria, Chemical substance, Mildew, Antimicrobial resistance, Korea Disease Control and Prevention Agency, Biological engineering, Growth, Calcium hydroxide, Bacteria, Health Canada, Chemical engineering, Virus, Safety, CO2, Environment, Textile, News, Auris, Food preservation, Vaccine, Uranium mining, Microbiology

TORONTO and CALGARY, Alberta, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is pleased to announce further advances in research and development of the Tri-Filler™ particle composed of Ca(OH)2 (calcium hydroxide) core with a CaCO3 (calcium carbonate) encapsulation.

Key Points: 
  • TORONTO and CALGARY, Alberta, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is pleased to announce further advances in research and development of the Tri-Filler™ particle composed of Ca(OH)2 (calcium hydroxide) core with a CaCO3 (calcium carbonate) encapsulation.
  • Preliminary testing points to the Tri-Filler™ being effective in inhibiting the growth of both gram-positive and gram-negative bacteria and fungi.
  • Biosenta has identified a number of industry partners with whom Biosenta and the University of Calgary team are in various stages of talks for further research and commercialization.
  • Biosenta Inc., a ground-breaking pioneer in the field of antimicrobial solutions, is on a mission to revolutionize the material world.

Federal, Provincial and Territorial Governments Jointly Release the Pan-Canadian Action Plan on AMR

Retrieved on: 
Thursday, June 22, 2023
Human, Antimicrobial, Action plan, Veterinarian, Public, Infection, Agriculture, AMR, Government, Indigenous peoples, Plant, Death, Animal, Antimicrobial resistance, National Action Plan to Combat Human Trafficking, Council, World Health Organization, Indigenous self-government in Canada, Health, Environment, Potential, Pharmaceutical industry

AMR can spread across geographical borders and between humans, animals, and their shared environments.

Key Points: 
  • AMR can spread across geographical borders and between humans, animals, and their shared environments.
  • Moving forward, the Government of Canada will continue to build on the collaborative work with provincial and territorial governments, Indigenous Peoples, industry stakeholders, and with partners across One Health sectors.
  • Through this Action Plan, together with provinces and territories we can protect the health of humans, animals and the environment against AMR."
  • The Action Plan builds on the 2017 Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan-Canadian Framework for Action , which was developed in collaboration with federal, provincial and territorial governments.

Newly Published Data Demonstrates Positive Outcomes Resulting from Pathnostics' Advanced Urinary Tract Infection (UTI) Test

Retrieved on: 
Tuesday, June 20, 2023
Diabetes, Urinary tract infection, UTI, University Challenge 2013–14, ABR, Cutis marmorata telangiectatica congenita, Number needed to treat, Drug resistance, Infection and Drug Resistance, SUC, Utilization, Antimicrobial resistance, Diagnosis, Medicare Part D, Health, Medical imaging, Nursing, Pharmaceutical industry, Hospital, Patient

IRVINE, Calif., June 20, 2023 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced the publication of two new studies demonstrating positive outcomes resulting from its advanced urinary tract infection (UTI) test. The studies show that treatment based on the company's Guidance® UTI test resulted in decreased health care resource utilization and costs compared to standard urine culture (SUC) tests, as well as reduced antibiotic resistance in patients with complicated urinary tract infections.

Key Points: 
  • In fact, average one-year costs related to UTIs were $501.85 lower for patients receiving treatment based on the Guidance® test than for those based on the traditional culture test.
  • In addition, results showed patients diagnosed via the Guidance® test had improved outcomes, including fewer inpatient episodes and lower inpatient costs.
  • Separately, data published in the peer-reviewed journal Infection and Drug Resistance suggests that treatment based upon Guidance® UTI testing resulted in reduced antibiotic resistance in symptomatic patients with suspected complicated UTIs.
  • "These new findings, combined with ongoing studies, support our mission of increasing access to advanced UTI testing that supports more informed treatment leading to improved outcomes."

NEW CERTIFICATION AIMS TO MITIGATE ANTIMICROBIAL RESISTANCE RISK IN ANTIBIOTIC MANUFACTURING

Retrieved on: 
Monday, June 5, 2023
Antibiotic, Lead, Maintenance, Poverty, Human, Partnership, BSI, Public, Infection, Roche, API, World Health Organization, AMR, Standard, Internal audit, Certification, World Environment Day, Trust, Nature, Antimicrobial resistance, Risk, UNEP, UN, Ecosystem, WHO, Environment, Aquaculture, Antibiotics, Airline, Fine chemical, Pharmaceutical industry, Teva, Novartis, Secretariat, Pfizer

LONDON, June 5, 2023 /PRNewswire/ -- BSI, the business improvement and standards company, today, on World Environment Day, launched a new global Minimized Risk of Antimicrobial Resistance (AMR) certification designed to promote and attest to the responsible manufacturing of antibiotics in the global supply chain, helping to minimize the risk of aquatic toxicity in the environment and the spread of AMR.

Key Points: 
  • Certification to the Antibiotic Manufacturing Standard will be a clear sign that manufacturers in the global antibiotic supply chain are taking necessary steps to ensure antibiotics are made responsibly, helping to minimize the risk of releasing antibiotic waste emissions into the environment.
  • After the initial launch, all antibiotic manufacturers globally will be eligible to seek certification by BSI.
  • "Ensuring antibiotic manufacturing meets best available scientific standards is an important tool in tackling the rise of antimicrobial resistance.
  • For more information on the AMR standard and certification program, visit: Antimicrobial resistance (AMR) and how standardization is driving change | BSI (bsigroup.com) .

One million human deaths linked to factory farming, set to double by 2050

Retrieved on: 
Friday, April 7, 2023
FSRA, HIV/AIDS, Meat, Human, Food, Life, Public, Antibiotic use in livestock, Cory Booker, Infection, Agriculture, Campylobacter, David Gal, Staphylococcus aureus, Chicken, Colon, Death, Sickness, Animal, Antimicrobial resistance, World Animal Protection, Water, Cancer, Salmonella, Health, Environment, Escherichia coli, Farm, Disease, Malaria, Poultry farming, Livestock

NEW YORK, April 7, 2023 /PRNewswire/ -- The excessive use of antibiotics in factory farming is causing the premature deaths of nearly one million people and $400 billion in global economic losses each year, according to a report titled Global Public Health Cost of Antimicrobial Resistance Related to Antibiotic Use on Factory Farms published today by World Animal Protection.

Key Points: 
  • In the first study of its kind, World Animal Protection has found that four superbugs common in factory farming – Staphylococcus aureus, Escherichia coli, Campylobacter, and non-typhoidal Salmonella – were linked to 975,000 human deaths and 35 million illnesses in 2019.
  • The report details how the human death toll linked to factory farming superbugs is on course to double by 2050 to 2 million if no immediate action is taken.
  • World Animal Protection is calling for a global moratorium on factory farming to safeguard animal welfare, human health, and the environment.
  • National governments must outlaw building new factory farms and expanding current farms to protect public health and farmed animals.